Format

Send to

Choose Destination
Semergen. 2016 May-Jun;42(4):260-2. doi: 10.1016/j.semerg.2015.08.008. Epub 2015 Dec 1.

[Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].

[Article in Spanish]

Author information

1
Atención Primaria, Centro de Salud Casas Ibáñez, Albacete, España; Facultad de Medicina, Universidad Católica San Antonio de Murcia (UCAM), Murcia, España; Grupo HTA SEMERGEN. Electronic address: jadivison@telefonica.net.
2
Servicio de Cardiología, Hospital La Paz, Madrid, España; Grupo HTA SEMERGEN.
PMID:
26653339
DOI:
10.1016/j.semerg.2015.08.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center